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The diagnosis of myocardial infarction requires careful evaluation of the presenting 
symptoms, electrocardiogram and evidence of myocardial necrosis.1 In recent years, high-
sensitivity cardiac troponin assays have transformed our ability to diagnose myocardial 
infarction by enabling the detection of myocardial necrosis with much greater degree of 
sensitivity and precision.2 The Universal Definition of Myocardial Infarction recommends 
use of the 99th centile upper reference limit as the threshold to define myocardial necrosis and 
provides distinct clinical criteria to differentiate between the different subtypes of myocardial 
infarction and myocardial injury.1 The importance of diagnosing type 1 myocardial infarction 
cannot be understated given the array of evidence-based therapies available. In contrast, there 
remains  a dearth of evidence-based strategies guiding management for type 2 myocardial 
infarction or  myocardial injury. Elevations in cardiac troponin concentrations in the high-
sensitivity era is common in patients who do not have type 1 myocardial infarction.3,4 
Furthermore, the prevalence of troponin elevations in patients without type 1 myocardial 
infarctions is compounded by different healthcare systems having different approaches to 
patient selection for troponin testing.5 Less selective use of troponin testing can significantly 
impact on the positive predictive value for the diagnosis of type 1 myocardial infarction and 
increase the difficulty in interpreting the results.5 
 
Etaher et al conducted a large prospective cohort study of 2,734 consecutive patients 
presenting with suspected acute coronary syndrome to a tertiary hospital. The study included 
all patients who received serial cardiac troponin measurements using a high-sensitivity 
cardiac troponin T assay with an upper reference limit of 14 ng/L. The medical records of all 
patients were reviewed by three consultant cardiologists who retrospectively adjudicated the 
final diagnosis according to the Fourth Universal Definition of Myocardial Infarction. 
Patients were subsequently followed up for up to 4 years for mortality, non-fatal myocardial 
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infarction and stroke. Elevated cardiac troponin was common with over a third of patients 
having concentrations above the 99th centile upper reference limit. The vast majority of 
patients had either myocardial injury or type 2 myocardial infarction with less than 1 in 10 
having a type 1 myocardial infarction.  Almost all patients with type 1 myocardial infarction 
received in-hospital coronary angiography. In contrast, a quarter patients with type 2 
myocardial infarction or acute myocardial injury and approximately one in every 30 patients 
with chronic myocardial injury. The same pattern was also observed in the use of evidence-
based pharmacotherapies across these patient groups. Patients with type 1 myocardial 
infarction had better outcomes compared to those with chronic myocardial injury or type 2 
myocardial infarction. Conversely, those with type 2 myocardial infarction in this cohort had 
the worst outcome, with over 3-fold higher risk of all-cause mortality at 4 years compared to 
those with type 1 myocardial infarction. This association persisted in a cox-proportional 
hazards model that adjusted for patient demographics, co-morbidities and smoking.  
 
Etaher et al should be commended for several important strengths in their study design. First, 
they recruited consecutive patients into the study. This approach avoided selection bias and 
ensured that the findings are representative of the broad patient population presenting to the 
Emergency Department with suspected acute coronary syndrome. Second, they conducted an 
exhaustive review of hospital and general practice medical records to achieve excellent 
phenotyping of the patient population. This is particularly important for patients with 
subtypes of myocardial infarction since they are more likely to have comorbidities. Such an 
approach also allowed the authors to include these variables into the Cox models to account 
for confounding when evaluating the relationship between subtype of myocardial injury and 
risk of death. Third, the authors had a robust adjudication process for the final diagnosis. In 
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particular, all patients in this cohort had serial high-sensitivity cardiac troponin measurements 
which allowed an accurate differentiation between acute and chronic myocardial injury.  
   
This analysis is an important addition to the literature in this field, particularly as high-
sensitivity cardiac troponin continues to be implemented more widely across the world.6 In 
this cohort, the prevalence of type 1 myocardial infarction was 3.5% (97/2738) and the 
corresponding positive predictive value of elevated cardiac troponin concentrations for the 
diagnosis of type 1 myocardial infarction was 9.7% (97/995). This was significantly lower 
compared to healthcare systems that use troponin testing more conservatively where positive 
predictive values have been reported to range between 45% and 65%.5  
  
Recent studies have demonstrated the utility of very low concentrations of high-sensitivity 
cardiac troponin assays in ruling out type 1 myocardial infarction in the Emergency 
Department.7,8 Conversely, implementing the 99th centile diagnostic threshold using a high-
sensitivity assay to rule-in the diagnosis did not improve patient outcomes.4 One of the major 
reasons for this observation is that the majority of those reclassified by the high-sensitivity 
assay had either type 2 myocardial infarction or myocardial injury reducing the positive 
predictive value for type 1 myocardial infarction. So how can we improve the positive 
predictive value of troponin testing for type 1 myocardial infarction? Various studies 
including that of Etaher et al illustrates the importance of patient selection for troponin 
testing with an indiscriminate approach significantly impacting on the positive predictive 
value. Other measures such as the application of clinical risk scores9 and machine-learning 
algorithms10 have also been suggested to improve the application and interpretation of high-
sensitivity cardiac troponin testing. It is also possible that the 99th centile upper reference 
limit may not be the appropriate diagnostic threshold for myocardial infarction as this was 
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defined from a statistical approach from different reference populations rather than for 
biological or clinical reasons.11 There is now significant data demonstrating that troponin 
varies significantly with age, sex and comorbidities.12,13 Whether a more nuanced approach to 
defining the decision limit for cardiac troponin requires further investigation.  
 
Consistent with many other observations, patients with type 2 myocardial infarction or acute 
myocardial injury in this cohort had poor outcomes.14,15 Etaher et al provided a useful 
breakdown of the final diagnosis of these patients which ranged from sepsis to acute heart 
failure and tachyarrhythmia. This is clearly a very heterogeneous group of patients with 
limited data at the moment to guide management of these patients. It is likely that the primary 
determinant of poor outcome in these patients is the severity of the acute illness coupled with 
significant underlying co-morbid status and frailty of these patients. Indeed, patients with 
type 2 myocardial infarction or acute myocardial injury in this cohort were on average 12 
years older than those with type 1 myocardial infarction, with significantly more 
comorbidities such as heart failure (22% versus 5%), atrial fibrillation (25% versus 5%), 
stroke (16% versus 10%), chronic kidney disease (49% versus 15%) and chronic obstructive 
pulmonary disease (19% versus 4%), therefore opportunities to improve their outcomes may 
be limited. Furthermore, a significant proportion of patients (43%) with type 2 myocardial 
infarction or acute myocardial injury did not undergo coronary angiography. Of those that did 
undergo coronary angiography, over a third had evidence of obstructive coronary disease. 
Whilst, it is plausible that this subgroup of patients may benefit from secondary preventative 
therapy no evidence base currently exists in this subgroup of patients. 
 
Conflict of Interest:  Dr Shah and Dr Lee have both received speaker fees from Abbott 
Diagnostics. 
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